Six Members of the U.S. House that 340B Stakeholders Should Keep an Eye on in 2025 By Ted Slafsky There are 435 members of the U.S. House and 100 U.S. Senators, and each one of them can influence the 340B drug discount program. But it is the lawmakers serving on two coveted committees, the House […]

Almost ten years ago, ASHP Midyear became the first conference at which the Verity Solutions name and logo were unveiled, and we showcased our 340B solutions. It’s astonishing how much we’ve grown and learned since then! Over the years, we’ve continued our commitment to optimizing pharmacy supply chain outcomes for better financial results and patient […]

Post Election Analysis: Implications for the 340B Program By Ted Slafsky With President-elect Donald Trump’s (R) big victory and the GOP takeover of the U.S. Senate in Tuesday’s elections, we are likely to see increased scrutiny over and additional efforts to place restrictions on the 340B program. On the positive side for 340B providers, U.S. […]

Verity Solutions Recognized #1 in KLAS 2024 Emerging Solutions Top 20 Report Verity Solutions’ VERISAVE® was recognized in the 2024 KLAS Emerging Solutions Top 20 Report. The top 20 emerging solutions were selected by healthcare leaders across the country from KLAS’ emerging solutions research. The aim was to find the solutions that had the greatest […]

Much-Needed Wins for 340B Providers but Challenges Could Be Lurking By Ted Slafsky After a long period in which many 340B providers felt helpless, the last month has brought two major wins. First, in a key decision on Sept. 30, a federal judge upheld Louisiana’s 340B contract pharmacy access law against lawsuits from the Pharmaceutical […]

CMS Should Heed the Advice of 340B Community on Medicare Negotiations By Ted Slafsky The Biden administration deserves credit for playing a key role in passing the first law in history to allow the government to negotiate lower drug prices for America’s 61 million Medicare beneficiaries. For several decades, many presidents—and even more presidential candidates—have […]

Unilateral Imposition of Rebate Model for the 340B Program is a Non-Starter By Ted Slafsky If things were not difficult enough already for 340B providers, hospitals woke up on Friday morning to an announcement that one of the world’s biggest drug manufacturers was moving forward with a plan to convert the 340B program to a […]

Three Key Observations from Efforts to Restore 340B Discounts in the States By Ted Slafsky After six months of heated battles in the states to restore access to 340B drug discounts in the contract pharmacy setting, it’s a good time to reflect on providers’ progress and setbacks.  Twenty-five states, an unprecedented number, have introduced bills […]

After 340B Hearing and New Bills Emerging; The Likely Path Forward By Ted Slafsky Despite its importance, the 340B drug discount program rarely ever goes under the Congressional spotlight.  In fact, until the June 4th House Energy & Commerce (E&C) Oversight and Investigations Subcommittee hearing, there had not been a hearing specifically devoted to the […]

Momentum Continues in States on Contract Pharmacy Access While Lowball Tactics Persist and Have Some Impact, Many States March Forward By Ted Slafsky In last month’s column, I wrote about a reprehensible campaign by 340B opponents to tie this critically important drug discount program to the contentious issue of immigration. A dark money campaign started […]